Today, Revance Therapeutics (RVNC) announced positive phase 2 results for their injectable drug, RT-002, that is being used to treat glabellar lines. What are glabellar lines? Basically those are skin wrinkles that form between the eyes - above the nose, and below the forehead. The phase 2 trial is treating 268 patients with three doses of the company's RT-002 injectable drug against a placebo -- marketed leader in space BOTOX. 

RT-002 like BOTOX is a botulinum toxin of type A, but is being designed in a way to limit treatment to injection site. The reason for this is to stop the spread of the botulinum toxin beyond the site of injection. The company believes that by localizing the site injection to one small area, it would create a longer-lasting effect of the intended injection target. 

The phase 2 results in the BELMONT study showed that all three doses given to patients over a 4-week period were statistically significant compared to BOTOX treatment. In addition RT-002 achieved a 100% response rate of 1 point in frown lines in 4-weeks based on the IGS-FWS scale. In comparison BOTOX achieved a 95% response rate in the same 4 week period. 

Revance even has other clinical programs in which it uses its delivery technology, known as TRANSITS peptide technology, which can also deliver drugs topically. While RT-002 is the company's injectable drug like BOTOX they are also working on a topical formulation that can be delivered without the need for skin injection. In addition to RT-002 being efficacious the company also noted that all three doses have no adverse effects making the treatment safe.